Sagimet Biosciences (STU:0O2) Total Long-Term Liabilities: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0O2 Sagimet Biosciences Inc STU:0O2
18 GF Score
Price €6.34
! 3 Warning Signs
View Full Analysis

What is Sagimet Biosciences Total Long-Term Liabilities?

Sagimet Biosciences STU:0O2 -3.94% 18 Total Long-Term Liabilities is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 18/100. The stock has 3 warning signs investors should review.

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Sagimet Biosciences's Total Long-Term Liabilities for the quarter that ended in Mar. 2026 was €0.00 Mil.

Sagimet Biosciences Total Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences Total Long-Term Liabilities Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Liabilities
Get a 7-Day Free Trial 190.14 202.68 0.00 0.00 0.00

Sagimet Biosciences Quarterly Data
Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:0O2
18GF Score
Sagimet Biosciences Inc STU:0O2
Total Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagimet Biosciences Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

What does a Total Long-Term Liabilities of €0.00 Mil mean?
Sagimet Biosciences (STU:0O2) has a Total Long-Term Liabilities of €0.00 Mil as of Mar. 2026. Toal Long-Term Liabilities is the obiligation expected to be repaid beyond the following twelve months or one business cycle. View historical data on Sagimet Biosciences and its competitors.
Is Sagimet Biosciences' Total Long-Term Liabilities too high?
Sagimet Biosciences' current Total Long-Term Liabilities is €0.00 Mil. Overall, Sagimet Biosciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Total Long-Term Liabilities compare to CABA and OVID?
Sagimet Biosciences' Total Long-Term Liabilities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Liabilities for a Biotechnology company?
A good Total Long-Term Liabilities depends on the Biotechnology industry context. However, Total Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Liabilities mean?
A high Total Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Toal Long-Term Liabilities is the obiligation expected to be repaid beyond the following twelve months or one business cycle. View historical data on Sagimet Biosciences and its competitors. Sagimet Biosciences's current Total Long-Term Liabilities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current Total Long-Term Liabilities of €0.00 Mil. The current Total Long-Term Liabilities is €0.00 Mil. Sagimet Biosciences' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Liabilities calculated?
Total Long-Term Liabilities is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Total Long-Term Liabilities is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
18GF Score

Get the complete analysis for STU:0O2

Total Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.34
Price